Trial Profile

Randomized comparison of Sequential therapies with Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sunitinib (Primary) ; Sorafenib
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms CROSS-J-RCC

Most Recent Events

20 Mar 2017 Status changed from active, no longer recruiting to completed, according to results presented at the 2017 Genitourinary Cancers Symposium.
18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
01 Feb 2014 Primary endpoint 'Progression-free-survival-duration' has not been met.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com